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The MEK1 oncoprotein plays a critical role in Ras/Raf/
MEK/MAPK-mediated transmission of mitogenic signals from
cell surface receptors to the nucleus. In order to examine this
pathway’s role in leukemic transformation, a conditionally
active (β-estradiol-inducible) form of the MEK1 protein was cre-
ated by ligating a cDNA encoding an N-terminal truncated form
of MEK1 to the hormone-binding domain of the estrogen recep-
tor (ER). We introduced this chimeric ∆MEK1:ER oncoprotein
into cytokine-dependent human TF-1 and murine FDC-P1 hema-
topoietic cell lines. Two different types of cells were recovered
after drug selection in medium containing either cytokine or β-
estradiol: (1) cells that expressed the ∆MEK1:ER oncoprotein
but remained cytokine-dependent and (2) MEK1-responsive
cells that grew in response to ∆MEK1:ER activation. Cytokine-
dependent cells were recovered 102 to 104 times more fre-
quently than MEK1-responsive cells depending upon the parti-
cular cell line. To determine whether BCL2 overexpression
could synergize with the ∆MEK1:ER oncoprotein in relieving
cytokine dependence, the cytokine-dependent ∆MEK1:ER-
expressing cells were infected with a BCL2-containing retro-
virus, and the frequency of MEK1-responsive cells determined.
BCL2 overexpression, by itself, did not relieve cytokine depen-
dency of the parental cells, however, it did increase the fre-
quency at which MEK1-responsive cells were recovered
approximately 10-fold. ∆MEK1:ER+BCL2 cells remained viable
for at least 3 days after estradiol deprivation, whereas viability
was readily lost upon withdrawal of β-estradiol in the MEK1-
responsive cells which lacked BCL2 overexpression. The
MAP kinases, ERK1 and ERK2 were activated in response
to ∆MEK1:ER stimulation in both ∆MEK1:ER and
∆MEK1:ER+BCL2 cells. As compared to the cytokine-depen-
dent ∆MEK1:ER and BCL2 infected cells, MEK1-responsive
BCL2 infected cells expressed higher levels of BCL2. While
both MEK1-responsive ∆MEK1:ER and ∆MEK1:ER+BCL2
infected cells expressed cDNAs encoding the autocrine cyto-
kine GM-CSF, more GM-CSF cDNAs and bioactivity were
detected in the MEK1-responsive ∆MEK1:ER+BCL2 cells than
in the MEK1-responsive cells lacking BCL2 or cytokine-depen-
dent cells. These conditionally transformed cells will be useful
in furthering our understanding of the roles MEK1 and BCL2
play in the prevention of apoptosis in hematopoietic cells. Leu-
kemia (2000) 14, 1080–1096.
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Introduction
The proliferation of many hematopoietic precursor cells is
promoted by interleukin-3 (IL-3), granulocyte/macrophage-
colony stimulating factor (GM-CSF), as well as certain other
growth factors.1–3 The loss of cytokine dependency by hema-
topoietic cells may be an important factor in the development
of leukemias.1,4–11 Cytokine-dependent human and murine
hematopoietic cell lines have been previously isolated.12–14
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The human IL-3/GM-CSF-dependent TF-1 cell line was iso-
lated from a patient with an erythroleukemia. The murine IL-
3/GM-CSF-dependent FDC-P1 cell line was isolated from the
bone marrow of a normal DBA/2 mouse and resembles cells
with a CFU granulocyte/macrophage morphology.12–14 Since
spontaneous factor-independent cells are rarely recovered
from TF-1 and FDC-P1 cell lines, these cell lines represent
attractive model systems to analyze the effects various
oncogenes have on signal transduction, loss of cytokine
dependence and leukemogenesis.1,4–11
IL-3 and GM-CSF exert their biological activity by binding
to the IL-3 and GM-CSF receptors, respectively (IL-3R and
GM-CSFR).15–21 These receptors activate a Janus (Jak2) protein
tyrosine kinase which leads to the phosphorylation and dimer-
ization of signal transducers and activators of transcription
(STATs).22,23 These STATs translocate to the nucleus where
they regulate the expression of various immediate–early
genes. In addition to Jak-STAT activation, receptor ligation
promotes phosphorylation of the Shc protein.24 Phosphoryl-
ated Shc results in the recruitment of a complex consisting of
Cbl/Grb2/Sos and the guanidine nucleotide exchange factor
Vav.25 This complex leads to the stimulation of Ras as well as
additional pathways.1 Activated Ras can promote the sequen-
tial activation of Raf, MEK and the MAP (ERK1 and ERK2)
kinases.26–29
Certain cytokines and interferons stimulate Jak activity
which can activate the Raf kinase pathway. Moreover, for
optimal activation of STAT binding activity, STAT dimers must
be phosphorylated on key serine residues by the MAP kinases,
ERK1 and ERK2, indicating that there is cross-talk between the
Jak-STAT and Raf/MEK/MAPK signaling pathways.27,30
Raf proteins transmit their regulatory signals to MEK1, a
dual specific serine/threonine and tyrosine kinase which phos-
phorylates the downstream MAP kinases (ERK1 and ERK2).
Activation of ERK1 and ERK2 ultimately results in the acti-
vation of transcription factors, such as Elk-1 and CREB, that
regulate gene expression.31–34 N-terminal deletion of the
MEK1 negative regulatory domain results in a constitutively
activated oncoprotein that can transform NIH-3T3 and Chi-
nese hamster ovary cells and abrogate the cytokine depen-
dency of certain hematopoietic cells.35–39 In addition, evi-
dence suggests that the Raf pathway is intimately associated
with the control of the apoptotic machinery in myelo–
monocytic cells.26,40
The efficiencies of abrogation of cytokine dependency of
hematopoietic cell lines by activated MEK1 are much lower
than that observed with v-Ha-Ras, v-Raf and other activated
oncoproteins.36,39,41–43 The nature of the inability of activated
MEK1 to relieve the cytokine dependency of most hematopo-
ietic cells has not been elucidated. We are interested in the
transforming capacity of MEK1 because it is located at pivotal
positions in both signal transduction as well as apoptotic
pathways.
A member of the apoptotic regulatory proteins, BCL2, has
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been described as a repressor of cell death.44,45 The bcl-2
gene was isolated from the chromosomal breakpoint of
t(14;18)-bearing follicular B cell lymphomas.44,45 B cells bear-
ing this translocation exhibit increased production of BCL2
and extended cell survival. BCL2 and related BCL-XL have
been shown to protect hematopoietic cell lines from apoptosis
following growth factor withdrawal.46
Cytokine stimulation has been documented to suppress
apoptosis via different mechanisms. The prevention of
apoptosis has been associated with the carboxyl region of the
IL-3R βc chain which is also responsible for the activation of
the Raf/MEK/MAPK cascade.26,40,47 Stimulation of appropriate
target cells by IL-3 leads to phosphorylation of Bad.48–50
Unphosphorylated Bad normally forms heterodimers with
anti-apoptotic factors, such as BCL2 or BCL-XL, to induce cell
death. When Bad is phosphorylated, it is bound and seques-
tered by the 14–3-3 family of proteins preventing its interac-
tion with BCL2 or BCL-XL.48–50 Thus, Bad is no longer associa-
ted with BCL2 or BCL-XL which allows them to bind Bax,
resulting in the prevention of apoptosis. Raf, Akt (also known
as protein kinase B (PKB)), ERK2, p90Rsk, and protein kinase A
(PKA) have all been shown to phosphorylate Bad.49,51 Recent
studies have also suggested roles for MEK1 in some of these
apoptotic pathways.52 Thus, signaling pathways have been
implicated in the regulation of anti-apoptotic pathways. Eluci-
dation of the sites of interaction and overlap of these pathways
may aid in our understanding, prevention and treatment of
leukemia.
Materials and methods
Cell lines and growth factors
Cells were maintained in a humidified 5% CO2 incubator with
Iscove’s modified Eagle’s medium (IMEM, Life Technologies;
Gaithersburg, MD, USA) complemented with 5% fetal bovine
serum (FBS, Atlanta Biologicals, Atlanta, GA, USA). The IL-
3/GM-CSF-dependent murine myeloid cell line FDC-P113,14
was cultured in medium supplemented with 10% WEHI-
3B(D−) conditioned medium (WCM) as a source of IL-3. The
human TF-1 cell line11,12 was purchased from the ATCC
(Rockville, MD, USA) and grown in RPMI 1640 (RPMI; Life
Technologies) containing 5% fetal bovine serum sup-
plemented with 1 ng/ml rGM-CSF (R&D systems, Minnea-
polis, MN, USA). MEK1-dependent FD/∆MEK1:ER and
TF/∆MEK1:ER cells were grown in RPMI + 5% BCS + 1 µm
β-estradiol or 500 nm 4-Hydroxy-Tamoxifen (4-HT; Sigma,
St Louis, MO, USA).
Retroviral infection of cells
Plasmid DNAs containing recombinant retroviruses were
transfected into the retroviral packaging cell lines ω2 or PA317
with lipofectin (Life Technologies). The retroviruses were
passed sequentially from one cell line to the other to amplify
their titers as described.6–8,39 FDC-P1 and TF-1 cells were
infected with viral stocks as described.6–8,39 The nomenclature
of the FDC-P1 or TF-1 cells is FD/∆MEK1:ER or TF/∆MEK1:ER,
for cells infected with the ∆MEK1:ER virus.53–55 After the ER
is the designation of whether the cells are IL-3-dependent
(IL3), GM-CSF-dependent (GM) or MEK1-responsive (Est). C
refers to a clone isolated by limiting dilution and pool refers
to a pool of cells. The following G418-resistant (neor) retro-
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viruses were used in this study: (1) LNL6, an empty retroviral
vector53,55 and (2) BCL2, the LNL6 retroviral vector encoding
sequences for the human BCL2 protein.46 Neor FDC-P1 or TF-
1 cells were isolated by selection in medium containing G418
(2 mg/ml; Life Technologies) and either cytokine (IL-3 or GM-
CSF) or β-estradiol.
Cell proliferation and 3H-thymidine incorporation
Cells were washed three times with phosphate-buffered saline
(PBS) before being set up for growth curves or proliferation
assays.39 Growth curves were performed in 5 ml of medium
with the indicated supplements in T25 tissue culture flasks
(Corning, Elmira, NY, USA). Cell proliferation assays were per-
formed in 96-well flat-bottom plates (Corning) with initially
104 cells/well that were incubated for either 1 (FDC-P1) or 3
(TF-1) days in the presence of the indicated supplements. Dur-
ing the last 6 h of incubation, DNA proliferation was meas-
ured by adding 3H-thymidine (6.7 Ci/mmol; NEN, Boston,
MA, USA) as described.7,8,39
In some cases ∆MEK1:ER cells were also cultured with 4-
OH Tamoxifen, also dissolved in ethanol which is an estro-
gen-receptor antagonist but activates the ∆MEK1:ER fusion
protein.39,54,56,57 ∆MEK1:ER-infected cells were also treated
with the MEK1 inhibitor, PD98059 (New England Biolabs
(NEB), Beverly, MA, USA)58,59 which was dissolved in dime-
thyl sulfoxide (DMSO; Sigma). Control cultures were set up
with DMSO and either cytokine or β-estradiol to measure the
toxicity of the solvent. In some cases, cells were treated with
the phorbol ester, phorbol 12-myristate-13-acetate (PMA;
Sigma) which activates protein kinase C (PKC) as a
control.60–63
Analysis of cell cycle distribution
Approximately 1 × 107 exponentially growing cells were
washed three times with PBS and then incubated at approxi-
mately 2 × 105 cells/ml in 25 ml of phenol red-free medium
containing BCS but lacking cytokine or β-estradiol. This initial
time point was designated (−24 h). Twenty-four hours later at
the T0 point, IL-3 (10%) or 4-HT (250 nm) was added to the
cultures. Aliquots of approximately 1 × 106 cells were sub-
sequently removed at 12 h intervals starting at the −24 h point.
Cell pellets prepared from the different incubation times and
culture conditions were resuspended in PBS and then fixed
and permeabilized in 70% ethanol overnight. The next day
the cells were collected by centrifugation and washed with
PBS containing 1% BSA. The cell pellets were resuspended in
0.5 ml of solution containing propidium iodide (50 µg/ml),
RNase (240 µg/ml) and Triton X-100 (0.01% v/v) and stained
for 30 min in the dark. The cell suspensions were passed
through a 25-gauge needle once before cell cycle analysis.
The percentage of cells in the various phases of the cell cycle
was analyzed on a Becton Dickinson FACS analyzer. The per-
centage of cells in the different phases of the cell cycle was
statistically analyzed using the ModFit 5.02 program.64
Polymerase chain reaction amplification of cytokine
mRNA transcripts
Total cytoplasmic RNA was prepared as described3,39,42,43 and
1 µg was included in a 20 µl cDNA synthesis reaction con-
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taining reverse transcriptase buffer, 1 mm of each dNTP, 20
mg/ml oligo-dT and 20 units Mo-MuLV reverse transcriptase.
After incubation at 42°C for 40 min, the reaction was termin-
ated by addition of H2O. For PCR amplification, 5 µl cDNA
was included in a 50 µl reaction mixture containing PCR
buffer, dNTPs, 1–2 units Taq polymerase and 1 mm of each
oligonucleotide primer. The primers for murine IL-3 were:
AATCAGTGGCCGGGATACCC and CGAAATCATCCAGATC
TCG defining a 200 bp cDNA fragment which could readily
be distinguished from a genomic IL-3 DNA fragment by size
(.1 kb). The primers for murine GM-CSF were: CCTGAG-
GAGGATGTGGCTGC and CTGTCCAAGCTGAGTCAGCG
defining a 601 bp fragment. The primers for murine β2-
microglobulin were TTCTCTCACTGACCGGCCTG and CAG-
TAGACGGTCTTGGGCTC defining a 308 bp fragment. The
primers for human GM-CSF were: CCTGGACTGGCTCCC
AGCAG and GATGTGGCTGCAGAGCCTGC defining a 425
bp fragment. The primers for human β-actin were: GAGAA-
GAGCTATGAGCTGCCT and TTCTGCATCCTGTCAGCAATG
defining a 236 bp fragment. The primers for human IL-3 were
CTCCTGCCGATCCAAACATGAG and AGAGGTTTCAGAA
GTTCTGCTG defining a 575 bp fragment. Thirty-five cycles
of PCR were performed to detect the cDNAs. The PCR pro-
ducts were electrophoresed on 1% agarose gels and vis-
ualized after ethidium bromide staining of the gel. Bands were
verified by Southern hybridization using a full-length probe.
Preparation of cell extracts and analysis by Western
blotting
Cells were washed twice with cold PBS and lysed on ice in
Gold lysis buffer (GLB) containing 20 mm Tris (pH 7.5), 137
mm NaCl, 5 mm Na2EDTA, 1% (vol/vol) Triton X-100, 15%
(vol/vol) glycerol, 1 mm phenylmethylsulfonyl fluoride, 10
µg/ml aprotinin, 10 µg/ml leupeptin, 1 mm sodium ortho-
vanadate, 1 mm ethylene glycol-bis (-aminoethyl ether)-
N,N,N9,N9tetra-acetic acid (EGTA), 10 mm sodium fluoride, 1
Table 1 Abrogation of cytokine dependency of ∆MEK1:ER clones after BCL2 infection
Initial cytokine-dependent Retrovirusa Selection conditionsb
cell line
Cytokine + G418c (%) β-Estradiol + G418 (%) DMEM + G418 (%)
FDC-P1 BCL2 384/384 (100) 0/384 (0) 0/384 (0)
LNL6d 384/384 (100) 0/384 (0) 0/384 (0)
Mock 0/384 (0) 0/384 (0) 0/384 (0)
FD/∆MEK1:ERc2e BCL2 384/384 (100) 126/384 (33) 0/192 (0)
LNL6 384/384 (100) 6/384 (1.5) 0/192 (0)
Mock 0/384 (0) 0/192 (0) 0/192 (0)
TF-1 BCL2 192/192 (100) 0/192 (0) 0/192 (0)
LNL6 192/192 (100) 0/192 (0) 0/192 (0)
Mock 0/192 (0) 0/192 (0) 0/192 (0)
TF/∆MEK1:ERc3e BCL2 192/192 (100) 52/192 (27) 0/192 (0)
LNL6 192/192 (100) 9/192 (5) 0/192 (0)
Mock 0/192 (0) 0/192 (0) 0/192 (0)
aThe retroviral stocks contained between 105 and 106 G418r retroviruses/ml.
b1 × 104 to 1 × 105 cells were plated in each well of a 96-well plate 2 days post infection in the presence of the indicated selective growth
conditions. Cytokine + G418 indicates: 10% IL-3 + 2 mg/ml G418 for FDC-P1 cells and 2 mg/ml GM-CSF + G418 for TF-1 cells. β-Estradiol
+ G418 indicates 1 µM β-estradiol + G418. G418 indicates 2 ng/ml of G418 was added to the basal media + 5% FBS.
cNumber of wells positive for growth/total number of wells examined.
dLNL6 is a retroviral vector which lacks an oncogene.
eFD/∆MEK1:ERc2 and TF/∆MEK1:ERc3 were determined to express the ∆MEK1:ER kinases, respectively, however, they were cytokine-
dependent clones.39 The number of times the particular infection was done is indicated by the total number of wells 4 96. Similar results
were obtained after infection of other cytokine-dependent FD/MEK1:ER and TF/∆MEK1:ER clones.
mm tetrasodium PPi, and 100 µm β-glycerophosphate. Insol-
uble material was removed by centrifugation at 15 000 g as
described.39,54,56,57 All chemicals were purchased from Sigma
unless otherwise indicated.
Cellular proteins were analyzed by electrophoresis through
polyacrylamide SDS gels followed by Western immunoblot-
ting on to polyvinylidene difluoride membranes (PVDF,
Immunobilon P; Millipore, Medford, MA, USA). Western blots
were incubated with the appropriate primary Ab at a dilution
of 1:500 (αERK2, αBCL-2; Santa Cruz Biotechnology (SCB),
Santa Cruz, CA, USA) to 1:1000 (αER; SCB) and then washed
in Tris-buffered saline containing 0.05% (vol/vol) Tween-20.
Antigen–antibody complexes were visualized by using
1:10 000-diluted protein A coupled to horseradish peroxidase
as indicated in the enhanced chemiluminescence detection
system (Amersham, Arlington Heights, IL, USA).39,54,56,57 The
blots were exposed to Kodak XAR5 X-ray film (Kodak,
Rochester, NY, USA) for 30 to 60 s.
Determination of MEK activity
MEK activity was measured by immunoprecipitating the
∆MEK1:ER protein from 100 µg total lysate with an αER Ab
(SCB) and protein A-sepharose beads as described.39,54 The
immunoprecipitates were then washed three times and used
in a kinase reaction for 30 min at 30°C in a reaction mix con-
taining: 100 mm HEPES, pH 7.4, 25 mm MgCl2, 1 mm DTT,
50 µm ATP, 10 µm 32P-ATP and 2 µg of bacterially expressed
rp42, an enzymatically-inactive form of MAP kinase (ERK2;
Upstate Biotechnology, Lake Placid, NY, USA). The reaction
mixtures were electrophoresed through a 10% polyacrylamide
gel, transferred to PVDF and exposed to X-ray film. The levels
of ∆MEK1:ER proteins used in the kinase assays were often
confirmed by probing the kinase blot with the αER Ab.
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Cells were deprived of either cytokine or β-estradiol for 24 h
in phenol red-free medium that contained 5% charcoal-
stripped BCS. The cells were then pulsed with cytokine or β-
estradiol for varying time points. Extracts were prepared as
previously described.39 ERK2 activity was determined, after
immunoprecipitation of 100 µg of total cell lysate with an
αERK2 antibody (SCB), using an in vitro radioactive kinase
assay with 43 mm HEPES, pH 7.4, 43 mm MgCl2, 200 µm
ATP, 2.3 µg myelin basic protein (MBP; Promega, Madison,
WI, USA), 10 µm α-32P-ATP and 0.5 mm DTT. The reactions
were electrophoresed through a 14% polyacrylamide gel,
transferred to PVDF and exposed to X-ray film. The levels of
ERK2 proteins used in the kinase assays were confirmed by
probing the blot with the αERK2 Ab.
Isolation of low molecular weight DNA for apoptosis
assays
1 × 107 cells (4 × 105 cells/ml) were grown in the indicated
conditions for 1 day.39 The cells were pelleted by centrifug-
ation, resuspended in 500 µl of lysis buffer (20 mm Tris-HCl,
pH 7.4, 10 mm EDTA, 0.2% Triton X-100) and placed on ice
for 10 min. The lysate was then centrifuged for 10 min at
14 000 r.p.m., and the pellet was discarded. Twenty-five µl
of 4 mg/ml protease K (Sigma) were added to the supernatant,
and the mixture was incubated overnight at room tempera-
ture. The solution was phenol extracted twice followed by
chloroform extraction once. The aqueous phase was saved
each time. The nucleic acids were ethanol precipitated and
subsequently resuspended in H2O. The concentration of the
Figure 1 Isolation of MEK1-responsive cells after infection of cytokine-dependent ∆MEK1:ER FDC-P1 and TF-1 cells with a BCL2 containing
retrovirus. Limiting dilution analysis of: panel (a) FD/∆MEK1:ER(IL3)c2+LNL6, (b) FD/∆MEK1:ER(IL3)c2+BCL2, (c) TF/∆MEK1:ER(GM)c3+LNL6
and (d) TF/∆MEK1:ER(GM)c3+BCL2. Growth in medium containing: (Κ), (IL-3, panels a and b), (GM-CSF, panels c and d), β-estradiol (µ) or
no supplement (Π). Dotted line equals 37% of wells negative for growth from which the differential plating efficiency was estimated by Poisson
distribution. Arrow on the X-axis indicates where the experimental data line intersects with the 37% negative for growth line and is an estimate
of the number of cells/well required to form a colony. These experiments were performed on four pools isolated from each type of ∆MEK1:ER
infected cells. Similar results were observed with two other clones of BCL2 and LNL6 infected FD/∆MEK1:ER and TF/∆MEK1:ER cells.
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nucleic acids was determined and 40 µg was treated with 10
µl of 0.1 mg/ml RNase A (Sigma) for 5–10 min. The remaining
DNA was electrophoresed in an agarose gel with 1× TBE (1×
= 0.09 m Tris borate, 0.002 m EDTA) running buffer and
visualized with ethidium bromide.
Results
Synergy between BCL2 and MEK1 in the abrogation
of cytokine dependency of human and murine
hematopoietic cells
It has been reported that the bcl-2 and raf oncogenes can
interact and may be involved in the prevention of apoptosis
in hematopoietic cells.65–67 Moreover, there is increasing evi-
dence indicating that ERK2, a downstream target of MEK1,
phosphorylates BCL2 which, in turn, stimulates the anti-apop-
totic activity of BCL2.68–70 The aim of the following experi-
ments was to determine whether BCL2 overexpression could
increase the frequency of hematopoietic cells which could
proliferate in response to activated ∆MEK1:ER. Uninfected
human TF-1 and murine FDC-P1 cells are strictly cytokine-
dependent, as they do not proliferate in the absence of IL-3
or GM-CSF. In the absence of appropriate cytokines these cell
lines undergo apoptosis within 1 to 2 days, respectively. The
overall design for the following experiments was to infect
cytokine-dependent FD/∆MEK1:ER and TF/∆MEK1:ER clones,
which express the ∆MEK1:ER oncoprotein, with either a
BCL2-containing retrovirus or the empty retroviral vector
(LNL6) and determine whether BCL2 overexpression could
increase the frequency of isolation of estradiol-responsive
cells.
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Table 2 Frequency of isolation of MEK1-responsive cells after
infection with an empty retroviral vector or a BCL2 containing
retrovirusa
Initial cytokine- MEK1- MEK1- Fold
dependent cell responsive responsive enhancement
line cells after cells after with BCL2
LNL6 infection BCL2 infection
FDC-P1 ,1 in 107 ,1 in 107 –
FD/∆MEK1:ERc2 1 in 2.5 × 104 1 in 2.5 × 103 10 ×
TF-1 ,1 in 104 ,1 in 104 –
TF/∆MEK1:ERc3 1 in 3.5 × 103 1 in 4 × 102 9
aDetermined by Poisson analysis as shown in Figure 1.
Three control infections were performed, infection of the
parental FDC-P1 and TF-1 cells with: (1) the BCL2 retrovirus,
(2) the empty retroviral vector and (3) a mock infection. Infec-
tion of parental FDC-P1 and TF-1 cells with BCL2 and LNL6
retroviruses resulted in the isolation of cells which grew in the
presence of cytokine and G418 but not in the absence of the
required cytokine (eg β-estradiol + G418) (Table 1). Thus,
parental FDC-P1 and TF-1 cells did not become factor-
independent after infection with BCL2 or the empty retroviral
vector. In addition, no mock-infected cells grew in
Figure 2 Growth of ∆MEK1:ER and BCL2 infected cells. The growth properties of three different types of ∆MEK1:ER infected cells are
compared. Panel (a) IL-3-dependent FD/∆MEK1:ER(IL3)c2+LNL6 cells, panel (b), MEK1-responsive FD/∆MEK1:ER+LNL6(Est)c4 cells, panel (c)
MEK1-responsive FD/∆MEK1:ER+BCL2(Est)c2 cells, panel (d), GM-CSF-dependent TF/∆MEK1:ER(GM)c3+LNL6 cells, panel (e), MEK1-responsive
TF/∆MEK1:ER+LNL6(Est)c1 cells, panel (f), MEK1-responsive TF/∆MEK1:ER+BCL2(Est)c1 cells. Growth in medium containing IL-3: (Κ, panels a,
b and c), GM-CSF (Κ, panels d, e and f), β-estradiol (Γ), or no supplement (Π). The data presented in Figure 2 are from triplicate sets of
experiments using two different clones.
G418-containing medium indicating that the selection
conditions were sufficient to isolate retrovirally-infected cells.
Next, cytokine-dependent FD/∆MEK1:ER and TF/∆MEK1:ER
cells were infected with the BCL2 virus, the empty retroviral
vector as well as mock infected (Table 1). BCL2 infection
increased the recovery of MEK1-responsive FD/∆MEK1:ER
and TF/∆MEK1:ER cells as compared with infection with the
empty retroviral vector. β-Estradiol was necessary for the
recovery of the cytokine-independent clones as no clones
were recovered in the absence of β-estradiol and cytokine
under G418 selection conditions. Thus, even in the presence
of constitutive BCL2 overexpression, the cells remained con-
ditionally factor-independent as they required β-estradiol to
proliferate.
Six different types of hematopoietic cells were isolated after
these infections: (1) cells which were infected with the empty
retroviral vector (LNL6) that remained cytokine-dependent; (2)
cells which were infected with BCL2 that remained cytokine-
dependent, (3) cells which were infected with ∆MEK1:ER and
LNL6 that remained cytokine-dependent; (4) cells which were
infected with ∆MEK1:ER and BCL2 which remained cytokine-
dependent; (5) cells which were infected with ∆MEK1:ER and
LNL6 that grew in response to β-estradiol in the absence of
exogenous cytokines; and (6) cells which were infected with
∆MEK1:ER and BCL2 that proliferated in response to β-estra-
diol in the absence of exogenous cytokines.
Effects of MEK1 and BCL2 on cytokine dependency
WL Blalock et al
1085
Figure 3 Stimulation of 3H-thymidine incorporation by β-estradiol and cytokines in the MEK1-responsive ∆MEK1:ER and BCL2 infected cells.
3H-thymidine incorporation was measured in the different MEK1-responsive cells. Symbols: (Κ) % IL-3 (% WEHI-3B conditioned supernatant,
panels a and c), (Κ) pg/ml GM-CSF (panels e and f). (Γ) nm β-estradiol. Panels (a and b) FD/∆MEK1:ER+LNL6(Est)c4, panels (c and d)
FD/∆MEK1:ER+BCL2(Est)c2, panels e and f) TF/∆MEK1:ER+LNL6(Est)c1, and panels (g and h) TF/∆MEK1:ER+BCL2(Est)c1. Similar results were
observed with four other FD/∆MEK1:ER+LNL6(Est) clones, six other FD/∆MEK1:ER+BCL2(Est) clones, three other TF/∆MEK1:ER+LNL6(Est) clones
and pools and four other TF/∆MEK1:ER+BCL2(Est) clones and pools.
Isolation of MEK1-responsive cells from pools of
∆MEK1:ER and BCL2 infected cells
To determine the frequency of isolation of MEK1-responsive
cells from ∆MEK1:ER and BCL2 infected FDC-P1 cells, limit-
ing dilution analysis was performed on the pools of infected
cells isolated in the presence of IL-3 and G418 (Table 2 and
Figure 1, panels a and b). The differences from the experi-
ments shown in Table 1 vs Figure 1 and Table 2 are that the
MEK1-responsive cells recovered in Table 1 were from direct
selection in β-estradiol and G418, whereas the MEK1-
responsive cells recovered in Figure 1 and Table 2 were from
pools of infected cells. Approximately 1 in 2 × 104
FD/∆MEK1:ER(IL3)c2+LNL6 cells could give rise to a colony
which grew in β-estradiol (Figure 1, panel a). BCL2
overexpression increased the frequency of isolation of FD/
Leukemia
∆MEK1:ER(IL3)c2 cells (FD/∆MEK1:ER(IL3)c2+BCL2; Figure 1,
panel b) that would grow in direct response to ∆MEK1:ER acti-
vation 10-fold in comparison to cells that were infected with
the empty retroviral vector. In contrast, cytokine-independent
cells were not isolated from pools of parental FDC-P1 cells
infected with either BCL2 or the empty retroviral vector (Table
2 and data not presented). These results have been summar-
ized in Table 2.
In order to determine whether a similar scenario was true
with the human TF/∆MEK1:ER cells, limiting dilution analysis
was performed with these cells. Limiting dilution analysis indi-
cated that 1 in 3.5 × 103 TF/∆MEK1:ER(GM)c3+LNL6 cells
would grow in the absence of exogenous GM-CSF in the pres-
ence of β-estradiol (Figure 1, panel c). Approximately nine-
fold more MEK1-responsive cells were recovered from BCL2
infected TF/∆MEK1:ER(GM) cells (TF/∆MEK1:ER(GM)c3+
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BCL2; Figure 1, panel d) than from empty retroviral vector
infected TF/∆MEK1:ER cells indicating that BCL2 over-
expression increased the recovery of cells which grew in
response to ∆MEK1:ER. As controls, the subcloning efficiency
of empty vector and BCL2 infected parental cells were exam-
ined. The pools of LNL6 and BCL2 infected parental TF-1 cells
did not give rise to cytokine-independent clones (Table 2 and
data not presented).
Growth properties of BCL2 and ∆MEK1:ER infected
FDC-P1 and TF-1 cells
To determine the growth properties of the ∆MEK1:ER cells
which overexpressed BCL2, growth curve experiments were
performed. Cytokine-dependent and FD/∆MEK1:ER(IL3)c2+
LNL6 cells proliferated in the presence but not the absence of
IL-3 (Figure 2, panel a). While β-estradiol did not promote
growth in cytokine-dependent FD/∆MEK1:ER(IL3)c2+LNL6
cells (Figure 2, panel a), it did stimulate the growth of the
MEK1-responsive FD/∆MEK1:ER+LNL6(Est)c4 cells (Figure 2,
panels b), however, these MEK1-responsive cells did not grow
in the absence of β-estradiol or IL-3 indicating that they were
conditionally transformed to MEK1-responsive growth.
IL-3 and β-estradiol stimulated the growth of the MEK1-
responsive FD/∆MEK1:ER+BCL2(Est)c2 cells (Figure 2). How-
ever, these cells displayed a definitive difference from their
MEK1-responsive FD/∆MEK:ER+LNL6 siblings as they did not
die as rapidly in the absence of IL-3 and β-estradiol (Figure
2, panel c).
Similarly, the cytokine-dependent TF/∆MEK1:ER(GM)c3+
LNL6 cells did not proliferate in the absence of GM-CSF and
β-estradiol (Figure 2, panel d). Only a slight increase in cell
numbers was observed when the cytokine-dependent cells
were cultured in β-estradiol. In contrast, the MEK1-responsive
TF/∆MEK1:ER+LNL6(Est)c1 cells proliferated in the presence
of either GM-CSF or β-estradiol (Figure 2, panel e). Finally, the
growth characteristics of the TF/∆MEK1:ER+BCL2(Est)c1 cells
were examined. While elevated numbers of these cells were
observed when they were cultured in either GM-CSF or β-
estradiol, relatively high numbers of these viable cells were
also observed when they were cultured in the absence of GM-
CSF and β-estradiol (Figure 2, panel f). However, these cells
did not continue to proliferate past 4 days in the absence of
GM-CSF and β-estradiol.
The ability of β-estradiol and IL-3/GM-CSF to
stimulate 3H-thymidine incorporation in BCL2 and
∆MEK1:ER infected hematopoietic cells
The sensitivities of the MEK1-responsive FD/∆MEK1:ER and
TF/∆MEK1:ER cells to cytokine and β-estradiol were examined
using 3H-thymidine incorporation assays, a measurement of
the ability of the activated MEK1 oncoprotein to promote
DNA synthesis. The FD/∆MEK1:ER+LNL6(Est)c4 cells incor-
porated 3H-thymidine in a dose-dependent fashion in
response to IL-3 (Figure 3, panel a). A lower level of 3H-thymi-
dine incorporation was observed in these cells in response to
β-estradiol (Figure 3, panel b). In contrast, the FD/∆MEK1:
ER+BCL2(Est)c2 cells had a higher basal level of 3H-thymidine
incorporation than the FD/∆MEK1:ER+LNL6(Est)c4 MEK1-
responsive cells and only showed an approximate two-fold
increase in response to either IL-3 or β-estradiol (Figure 3,
panels c and d).
Similarly, 3H-thymidine incorporation was observed in a
dose-dependent fashion in response to either β-estradiol or
GM-CSF in the MEK1-responsive TF/∆MEK1:ER+LNL6(Est)c1
and TF/∆MEK1:ER+BCL2(Est)c1 cells; however, the responses
were higher with GM-CSF than with β-estradiol (Figure 3,
panels e–h).
Stimulation of 3H-thymidine incorporation by 4-
Hydroxy-Tamoxifen
In order to determine whether endogenous estrogen receptors
could be synergizing with MEK1 in the MEK1-responsive cells
to lead to cytokine independence, the ability of the estrogen-
receptor antagonist 4-OH Tamofixen (4-HT) to promote
growth of the MEK1-responsive cells was examined (Figure 4).
4-HT inhibits endogenous estrogen receptors but activates the
∆MEK1:ER fusion protein. MEK1-responsive FD/∆MEK1:ER
+LNL6(Est)c4 (Figure 4, panel a) and FD/∆MEK1:ER+BCL2(Est)
c2 (Figure 4, panel b) cells incorporated 3H-thymidine in
response to 4-HT. Similar results were observed with the
TF/∆MEK1:ER+LNL6 and TF/∆MEK1:ER+BCL2 clones (Figure
4, panels c and d). These experiments eliminated the possi-
bility that endogenous estrogen-receptors functioned either
alone or in synergy with the activated ∆MEK1:ER protein to
stimulate proliferation of the MEK1-responsive cells.
Figure 4 Stimulation of 3H-thymidine incorporation by 4-OH
Tamoxifen in the estradiol-responsive ∆MEK1:ER and BCL2 cells. The
ability of 4-HT to promote 3H-thymidine incorporation was measured
in the MEK1-responsive cells. Symbol: (ε) 4-HT. Panels (a)
FD/∆MEK1:ER+LNL6(Est)c4, (b) FD/∆MEK1:ER+BCL2(Est)c2, (c)
TF/∆MEK1:ER+LNL6(Est)c1, and (d) TF/∆MEK1:ER+BCL2(Est)c1.
Similar results were observed with four other FD/∆MEK1:ER+LNL6,
six other FD/∆MEK1:ER+BCL2(Est) clones, three other
TF/∆MEK1:ER+LNL6(Est) clones and pools and four other
TF/∆MEK1:ER+BCL2(Est) clones and pools.
Effects of MEK1 and BCL2 on cytokine dependency
WL Blalock et al
1087
Figure 5 Modfit histogram analysis of cell cycle distribution. Top panels: Cell cycle progression in cytokine-dependent FD/BCL2(IL3) cells.
Bottom panels: FD/∆MEK1:ER+BCL2(Est)c2 cells. In these histograms, the cell number was cut off at 500 in order to show the proportion of
cells in S and G2/M better. The actual percentages of the cells in the different phases are presented in Figure 6. Panel (a) represents the start
of the experiments (−24 h). Panel (b) represents −12 h before the start of addition of cytokines or 4-HT. Panel (c) represents the time of addition
(T0) of cytokine or 4-HT. Panel (d) represents cells cultured without IL-3 and 4-HT for an additional 24 h. Panel (e) represents cells cultured
with IL-3 for 24 h. Panel (f) represents cells cultured with 4-HT for 24 h. Panel (g) represents cells cultured without IL-3 and 4-HT for an
additional 48 h. Panel (h) represents cells cultured with IL-3 for 24 h. Panel (i) represents cells cultured with 4-HT for 48 h. Shaded peak: G1;
stripped peak: S; and open peak: G2/M. Cells in panels (d, e and f) were collected at the same time and cells in panels (g, h and i) were
collected at the same time. The percentages of cells in the G1, S and G2/M phases of the cell cycle are presented in each panel for each
condition and time point.
Effects of ∆MEK1:ER and BCL2 expression on cell
cycle progression
Raf and downstream MEK and ERK have been shown to
influence the cell cycle by regulating the expression of the
Leukemia
p21Cip1 cell cycle inhibitory protein.71 In addition, cell cycle
and apoptotic regulatory proteins are typically the targets of
anti-neoplastic drugs. Therefore, in order to examine the
effects of aberrant MEK1 activation and BCL2 expression on
cell cycle progression, we performed cell cycle analyses on
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both the cytokine-dependent and MEK1-responsive FDC-P1
cells. This analysis allowed the examination of the percentage
of cells in each phase of the cell cycle in response to cytokine
stimulation or MEK1 activation (Figures 5 and 6). Initially,
cells were starved of IL-3 or β-estradiol for 24 h and then
stimulated with either IL-3 or 4-HT, which was used in place
of β-estradiol. After staining with propidium iodide, the per-
centage of cells in the individual phases of the cells cycle was
examined by FACS and the Modfit 5.02 computer program.
A diagrammatic example of the effects of MEK1 on cell cycle
distribution is presented in Figure 5. Two examples,
FD/BCL2(IL3) (top panel) and FD/∆MEK1:ER+BCL2(Est)c2
(bottom panel), are presented to show how these cell lines
differ in their distribution of cells in the various cell cycle
phases after stimulation with IL-3 or 4-HT. Note that after 24 h
of starvation, a significant percentage of the FD/∆MEK1:ER+
BCL2(Est)c2 cells still remained in S and G2/M phases (bottom,
panel c). In contrast, the proportion of FD/BCL(IL3) cells in
the S and G2/M phases was greatly diminished (top, panel c).
Moreover, the effects of 4-HT on cell cycle progression dif-
fered greatly between the cell lines. A significant percentage
of the cytokine-dependent FD/BCL2 (IL3) cells did not enter
S phase in response to 4-HT while a significant percentage
of the MEK1-responsive FD/∆MEK1:ER+BCL2(Est)c2 cells
entered S and G2/M phases in response to 4-HT.
The extent of cell cycle progression was examined in the
other cytokine-dependent and MEK1-responsive ∆MEK1:ER
and BCL2 infected FDC-P1 cells. These data represent the
average of three to six time course experiments and are
presented graphically in Figure 6. Initially (designated −24 h),
approximately 25% of the IL-3-dependent and MEK1-respon-
sive cells were in the S phase of the cell cycle which is charac-
Figure 6 Effects of MEK1 and BCL2 on cell cycle progression in FDC-P1 cells. The percentage of cells in the G1, S and G2/M phases of the
cell cycle of the indicated cell lines were statistically determined by the Modfit 5.02 computer program after deprivation of cytokine or β-
estradiol and then treatment with either IL-3 (λ), 4-HT (γ) or no addition (π). −24 indicates the start of the experiments, 0 indicates when
either IL-3 or β-estradiol was added. Panels (a, b and c) FDC-P1, panels (d, e and f) FD/BCL2(IL3)Pool, panels (g, h and i) FD/∆MEK1:ER(IL3)c2,
panels (j, k and l) FD/∆MEK1:ER+LNL6(Est)c4 and panels (m, n and o) FD/∆MEK1:ER+BCL2(Est)c2 cells. These experiments were repeated three
to six times and then averaged together.
teristic of this cell line when it is proliferating exponentially
(Figure 6, panels b, e, h, k and n).
The level of cytokine-dependent cells in S phase dropped
to approximately 5% after 24 h of cytokine deprivation (Figure
6, panels b, e and h). Likewise, the percentage of cytokine-
dependent cells in G2/M decreased from approximately 10%
to 5% 24 h after withdrawal of cytokine (Figure 6, panels c,
f and i) while the percentage of cells in G1 increased from
approximately 65% to 90% (Figure 6, panels a, d and g). Thus,
removal of cytokine from the cytokine-dependent cells
resulted in the cells exiting the S and G2/M phases and
entering the G1 phase of the cell cycle.
Upon stimulation with IL-3 at T0, each of the cytokine-
dependent cell lines entered the cell cycle (Figure 6, panels
a–i). In contrast, while only very few parental FDC-P1 and
FD/BCL2(IL3) cells entered the cell cycle in response to 4-HT,
a small but significant percentage (12%) of the
FD/∆MEK1:ER(IL3)c2 cells responded to 4-HT and entered S
phase (Figure 6, panels b, e and h).
In sharp contrast to the cytokine-dependent cells,
cytokine/β-estradiol deprivation of the MEK1-responsive
FD/∆MEK1:ER+LNL6(Est)c4 (Figure 6, panel k) and FD/
∆MEK1:ER+BCL2(Est)c2 (Figure 6, panel n) cells did not result
in as many cells exiting S and G2/M phases of the cell cycle.
After 24 h of deprivation, higher percentages of the MEK1-
responsive cells, approximately 12.5% of the
FD/∆MEK1:ER+LNL6(Est)c4 cells (Figure 6, panel k) and 20%
of the FD/∆MEK1:ER+BCL2(Est)c2 cells (Figure 6, panel n)
remained in S phase. Treatment of the MEK1-responsive cells
with IL-3 resulted in approximately 40% of the cells entering
S phase by 24 h. In addition, unlike in the cytokine-dependent
cells where treatment with 4-HT only had a modest effect,
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treatment of the MEK1-responsive cells resulted in 25% to
30% of the FD/∆MEK1:ER+LNL6(Est)c4 (Figure 6, panel k) and
FD/∆MEK1:ER+BCL2(Est)c2 (Figure 6, panel n) cells entering S
phase, respectively. In summary, the cytokine-dependent cells
seemed to be blocked from entering S phase in response to
4-HT. BCL2 overexpression alone in the parental FDC-P1 cells
was not able to relieve this block in the cell cycle, but in
synergy with ∆MEK1:ER, BCL2 overexpression was able to
lead to cell cycle progression. This same ability was seen in
the MEK1-responsive cells infected with only the empty retro-
viral vector, FD/∆MEK1:ER+LNL6(Est)c4. As will be discussed,
these cells were found to overexpress endogenous BCL2.
BCL2 overexpression prevents apoptosis in ∆MEK1:ER
infected cells
BCL2 expression has been linked to the prevention of
apoptosis in hematopoietic cells.1 In order to determine
whether BCL2 overexpression would synergize with
∆MEK1:ER in the prevention of apoptosis, low molecular
weight DNA was prepared from cells grown for one day under
the indicated conditions (Figure 7). In these experiments, the
presence of an apoptotic DNA ladder indicates that the cells
have undergone apoptosis, whereas the absence of an apop-
totic ladder suggests that the cells have not undergone
apoptosis. When the IL-3-dependent cell lines FDC-P1 (Figure
Figure 7 BCL2 overexpression prevents apoptosis in ∆MEK1:ER infected cells. Low molecular weight DNA was prepared from the indicated
cell lines that had been grown in the indicated conditions for 1 day and electrophoresed on a 1.5% agarose gels. These experiments were
repeated two to six times and similar results were observed with the different cell lines.
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7, panel a, lanes 1 and 3), FD/∆MEK1:ER(IL3)c1 (Figure 7,
panel a, lanes 4 and 6), or FD/BCL2 (Figure 7, panel b, lanes
1 and 3) were cultured in the absence of IL-3, the cells
underwent apoptosis. In contrast, when the same cells were
cultured in IL-3 (Figure 7, panel a, lanes 2, 5, and panel b,
lane 2) the cells did not undergo apoptosis. Interestingly, the
apoptotic DNA ladder obtained from the FD/BCL2 cells was
not as intense as that observed from the parental FDC-P1 and
FD/∆MEK1:ER(IL3)c1 cells. This reproducible result suggests
BCL2 was hindering apoptosis in the FD/BCL2 cells but was
unable to completely block apoptosis.
When the MEK1-responsive FD/∆MEK1:ER(Est)c1 cells were
cultured in the absence of IL-3 or β-estradiol the cells
underwent apoptosis (Figure 7, panel a, lane 7). In contrast,
when these cells were cultured with either IL-3 (Figure 7,
panel a, lane 8) or β-estradiol (Figure 7, panel a, lane 9), the
cells did not undergo apoptosis. Similar results were obtained
when 4-HT was used in place of β-estradiol (data not
presented). Thus, ∆MEK1:ER activation prevented the appear-
ance of an apoptotic DNA ladder in the MEK1-responsive
cells in the absence of IL-3.
Apoptosis was not observed when the estradiol-responsive
FD/∆MEK1:ER+BCL2(Est)c2 cells were cultured in the absence
of IL-3 or β-estradiol (Figure 7, panel b, lane 4). Nor was
apoptosis observed when these cells were cultured in the pres-
ence of IL-3 (Figure 7, panel b, lane 5) or β-estradiol (Figure
7, panel b, lane 6). The FD/∆MEK1:ER+BCL2(Est)c2 cells typi-
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cally had to be deprived of cytokine and β-estradiol for 48 h
before a detectable apoptotic ladder was visible. Thus, BCL2
overexpression in conjunction with ∆MEK1:ER expression
suppressed apoptosis in these cells to a greater degree than
BCL2 alone (Figure 7, panel b, lanes 4–6). As seen in Figure
2, the FD/∆MEK1:ER+BCL2(Est)c2 cells typically took several
days to die after cytokine withdrawal.
Effects of ∆MEK1:ER and BCL2 on MEK1 and
downstream kinase activities
The levels of MEK1 kinase activity were examined in the
MEK1-responsive FDC-P1 and TF-1 cells. A dose–response
curve of β-estradiol on MEK1 activity was performed with the
FD/∆MEK1:ER+LNL6(Est)c4 and FD/∆MEK1:ER+BCL2(Est)c2
cells by depriving them of β-estradiol for 24 h and then treat-
ing them with varying concentrations of β-estradiol for 4 h.
The ∆MEK1:ER encoded kinase was regulated by β-estradiol
in the FD/∆MEK1:ER+LNL6(Est)c4 cells (Figure 8) as higher
levels of kinase activity were detected when the cells were
stimulated with increasing concentrations of β-estradiol
(Figure 8, panel a). In contrast, after 24 h of cytokine-depri-
vation and then treatment with β-estradiol there did not
appear to be a significant difference in the level of MEK1 kin-
Figure 8 β-estradiol induces MEK1 and downstream map kinase activities in MEK1-responsive ∆MEK1:ER and BCL2 infected cells. Panel
(a) FD/∆MEK1:ER+LNL6(Est)c4 and panel (b) FD/∆MEK1:ER+BCL2(Est)c2 cells were deprived of β-estradiol for 24 h and then cultured with the
indicated concentrations of β-estradiol or IL-3 (10% WCM) for 4 h. Lysates were prepared and MEK1 activity determined. Panel (c) MEK1 activity
was determined in FD/∆MEK1:ER+BCL2(Est)c2 cells that were deprived of β-estradiol for 24 h and then stimulated with either IL-3 (10% WCM),
or 1 µm β-estradiol. MEK1 activity was determined in cells cultured for either 24 or 48 h in the indicated conditions in panels (d, e, f, g, h, i
j, k and l), cells were cultured with β-estradiol (1 µm), cytokines (10% IL-3, panels d, e, f, g and h or 500 pg/ml rGM-CSF, panels i and k).
Some cells (panels e, h, j and l) were also treated with β-estradiol (1 µm) and PD98059 (50 µm) or 0.05% DMSO (used to dissolve PD98059).
Panels (m, n, o and p) ERK2 activity in cells which were deprived of β-estradiol for 24 h and then stimulated with cytokines IL-3 (10%, panels
m and n), GM-CSF (500 pg/ml panels o and p) or β-estradiol (1 µm) for the indicated time periods.
ase detected in the FD/∆MEK1:ER+BCL2(Est)c2 cells (Figure 8,
panel b). This result is consistent with the cell cycle data
presented in Figure 5 which indicated that a higher proportion
of these cells remained in the S phase of the cell cycle after
cytokine withdrawal. Often, culture of the
FD/∆MEK1:ER+BCL2(Est)c2 cells in the absence of β-estradiol
for 2 days was necessary to reduce the level of ∆MEK1:ER
kinase activity to background levels (see Figure 8, panel g
below). The ∆MEK1:ER kinase blots were subsequently
probed with an αER Ab to measure the amount of ∆MEK1:ER
protein used in the kinase assay. The level of the ∆MEK1:ER
protein was seen to increase with higher concentrations of β-
estradiol. This is believed to be a result of the ability of β-
estradiol to stabilize the ∆MEK1:ER protein.54,56,57
The kinetics of MEK1 activation were examined in
FD/∆MEK1:ER+BCL2(Est)c2 cells which had been deprived of
cytokine and β-estradiol for 24 h. As observed in panel c, the
basal level of MEK1 activity in the FD/∆MEK1:ER+BCL2(Est)c2
cells was reasonably high, but upon treatment with IL-3 or β-
estradiol, MEK1 activity increased initially at 15 min and again
from 4 to 12 h after stimulation.
MEK1 activity was also examined in MEK1-responsive
FD/∆MEK1:ER+LNL6(Est)c4 and FD/∆MEK1:ER+BCL2(Est)c2
cells which had been cultured for 24 or 48 h in the absence
of IL-3 and β-estradiol or in the presence of IL-3, IL-3 and β-
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estradiol or β-estradiol alone (Figure 8, panels d–h). For these
experiments the cells were not previously deprived of cyto-
kine or β-estradiol. When the MEK1-responsive FD/∆
MEK1ER+LNL6(Est)c4 and FD/∆MEK1:ER+BCL2(Est)c2 cells
were cultured in the absence of either IL-3 or β-estradiol for
24 hrs, a background basal level of MEK1 activity was
observed (Figure 8, panels d and f, lane 1). Likewise, a basal
level of MEK1 activity was observed when they were cultured
with IL-3 for 24 h (lane 2). In contrast, when these cells were
cultured with β-estradiol and IL-3 (lane 3) or β-estradiol (lane
4), higher levels of MEK1 activity were observed. When the
FD/∆MEK1:ER+BCL2(Est)c2 cells were deprived of β-estradiol
for 48 h (Figure 8, panel g, lane 1) or cultured in the presence
of IL-3 for 48 h (lane 2), no MEK1 activity was detected. This
is most likely due to the fact that when these cells are cultured
in the absence of β-estradiol for a prolonged period of time,
the level of the ∆MEK1:ER protein decreased significantly (see
∆MEK1:ER protein levels, bottom part of Figure 8, panel g),
as β-estradiol is necessary for the presence and stability of
the protein. In contrast, when the FD/∆MEK1:ER+BCL2(Est)c2
cells were grown in the presence of either β-estradiol and IL-
3 (Figure 8, panel g, lane 3) or β-estradiol (lane 4) for 48 h,
MEK1 activity was detected.
The effects of the MEK1 inhibitor, PD98059, on MEK1
activity in FD/∆MEK1:ER+LNL6(Est)c4 (Figure 8, panel e) and
FD/∆MEK1:ER+BCL2(Est)c2 (Figure 8, panel h) cells were
examined. MEK1 activity was detected in higher levels in the
cells that had been treated for 24 h with β-estradiol (Figure 8,
panels e and h, lane 2) or β-estradiol and DMSO (Figure 8,
panels e and h, lane 3) than with β-estradiol and the MEK1
inhibitor (Figure 8, panels e and h, lane 4). Thus the MEK1
inhibitor suppressed the levels of MEK1 activity in response
to β-estradiol.
Similarly, the level of MEK1 activity in the MEK1-responsive
TF/∆MEK1:ER+LNL6(Est)c1 and TF/∆MEK1:ER+BCL2(Est)c1
cells (Figure 8, panels i–l) was usually detected at higher levels
when the cells were treated with GM-CSF and β-estradiol or
Figure 9 Expression of the BCL2 oncoprotein in MEK1-responsive cells. The expression of the BCL2 oncoprotein was examined in
parental+BCL2, ∆MEK1:ER+LNL6 and ∆MEK1:ER+BCL2 cells by Western blot analysis. To examine the level of BCL2 protein expression, cells
were deprived of β-estradiol and serum for 4 h and then treated with the indicated supplements. BCL2 was immuno-
precipitated, run on 14% polyacrylamide gels and blotted with the αBCL2 Ab. Panel (a) FD/BCL2(IL3), panel (b) FD/∆MEK1:ER(IL3)c2, panel
(c) TF/BCL2(GM), panel (d) TF/∆MEK1:ER+BCL2(GM)Pool, panel (e) FD/∆MEK1:ER+LNL6(Est)c4, panel (f) FD/∆MEK1:ER+BCL2(Est)c2, panel (g)
TF/∆MEK1:ER+LNL6(Est)Pool and panel (h) TF/∆MEK1:ER+BCL2(Est) Pool.
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β-estradiol (Figure 8, panels i and k, lanes 3 and 4) than when
they were treated with GM-CSF alone (Figure 8, panels i and
k, lane 2). Likewise, the MEK1 inhibitor also suppressed MEK1
activity in these cells (Figure 8, panels j and l, lane 3).
The ability of cytokine and β-estradiol to induce ERK2
activity was examined in the FD/∆MEK1:ER+LNL6(Est)c4,
FD/∆MEK1:ER+BCL2(Est)c2, TF/∆MEK1:ER+LNL6(Est)c1, and
TF/∆MEK1:ER+BCL2(Est)c1 estradiol-responsive cells (Figure
8, panels m–p). Both β-estradiol and cytokine induced ERK2
activity as early as 15–30 min after addition to the cytokine-
deprived cells. The level of ERK2 activity typically peaked
initially at 1–2 h after stimulation but then peaked again
around 8–12 h after stimulation and remained elevated for up
to 24 h (Figure 8, panels m–p).
Expression of the BCL2 oncoprotein in the ∆MEK1:ER
and BCL2 infected cells
The expression of the BCL2 oncoprotein was examined in the
parental FDC-P1 and TF-1 cells infected with BCL2 as well as
the ∆MEK1:ER+LNL6 and ∆MEK1:ER+BCL2 cells. Over-
expression of BCL2 was detected in the parental cells infected
with BCL2 alone (Figure 9, panels a and c). However, no cyto-
kine-dependent clones were ever recovered from these pools.
In the FD/∆MEK1:ER(IL3)c2 cells, endogenous expression of
BCL2 was barely detectable (Figure 9, panel b). The level of
BCL2 in these cells appeared to increase at 15–30 min after
IL-3 or 4-HT stimulation but then rapidly fell to background
levels by 2 h. In contrast, the FD/∆MEK1:ER cells infected with
BCL2 expressed constitutively elevated levels of BCL2 as com-
pared to uninfected FD/∆MEK1:ER cells. The levels of the
overexpressed BCL2 in these cells did not vary significantly
with the different treatments. Interestingly, the MEK1-respon-
sive FD/∆MEK1:ER+BCL2 cells, were found to express higher
levels of BCL2 as compared to the cytokine-dependent
FD/∆MEK1:ER+BCL2 cells (Figure 9, panel f and data not
shown).
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As expected, the level of BCL2 detected in the cytokine-
dependent FD/∆MEK1:ER+LNL6 cells was similar to that
observed in the uninfected FD/∆MEK1:ER cells (data not
shown). Surprisingly though, it was found that the MEK1-
responsive FD/∆MEK1:ER+LNL6(Est)c4 cells expressed levels
of endogenous BCL2 comparative to the levels observed in
the MEK1-responsive FD/∆MEK1:ER+BCL2 cells (Figure 9,
panel e).
Much like that observed in the FD/∆MEK1:ER+BCL2 cells,
BCL2 levels were found to be constitutively elevated in the
TF/∆MEK1:ER+BCL2 cells, with the MEK1-responsive cells
expressing the higher levels of BCL2 as compared to the cyto-
kine-dependent TF/∆MEK1:ER+BCL2 cells (Figure 9, panels d
and h). In contrast to the MEK1-responsive FD/∆MEK1:ER+
LNL6(Est)c4 cells, the MEK1-responsive TF/∆MEK1:ER+LNL6
(Est) cells did not express elevated levels of BCL2 and there-
fore were transformed to cytokine independence by some
additional mechanism (Figure 9, panel g).
Autocrine growth factor synthesis by ∆MEK1:ER and
BCL2 infected cells
To determine whether there was a possible autocrine compo-
nent to the growth induced by ∆MEK1:ER and BCL2, the pres-
ence of autocrine growth factors was determined by examin-
ing the ability of the supernatants to stimulate the growth of
the parental cell lines (Figure 10). The supernatant prepared
from FD/∆MEK1:ER+BCL2(Est)c2 and TF/∆MEK1:ER+BCL2
(Est)c1 cells readily supported 3H-thymidine incorporation in
the parental FDC-P1 (Figure 10, panel a) and TF-1 cells (Figure
10, panel b). The cytokine secreted by MEK1-responsive
FD/∆MEK1+BCL2(Est)c2 and TF/∆MEK1:ER+BCL2(Est)c1 cells
was determined to be GM-CSF by neutralization experiments
with αGM-CSF and αIL-3 antibodies (data not presented).
Moreover, the level of GM-CSF production was sufficient to
support the growth of parental FDC-P1 (Figure 10, panel c)
and TF-1 (Figure 10, panel d) cells. The significance of this
autocrine growth factor production was further examined by
treatment of the cells with an αGM-CSF antibody. Treatment
of MEK1-responsive FD/∆MEK1:ER+BCL2(Est)c2 and
TF/∆MEK1:ER+BCL2(Est)c1 cells with the anti-GM-CSF anti-
body reduced 3H-thymidine incorporation by approximately
50%. In contrast, treatment of the cells with an αIL-3 antibody
or control antibody, of the same immunoglobulin subclass,
did not inhibit 3H-thymidine incorporation (Figure 10, panel
e). Autocrine GM-CSF secretion was also detected in the
MEK1-responsive FD/∆MEK1:ER+LNL6(Est)c4 and TF/∆MEK1:
ER+LNL6(Est)c1 cells. However, the level of GM-CSF
secretion was 2.5- to 5-fold lower than that detected in the
MEK1-responsive cells which express the BCL2 oncogene
(data not presented, see below).
Presence of GM-CSF cDNAs in the ∆MEK1:ER and
BCL2 infected cells
To provide further evidence that the bioactivity that was
detected was indeed GM-CSF, the presence of GM-CSF and
IL-3 cDNAs was examined by RT-PCR (Figure 11). As a con-
trol, the presence of IL-3 and GM-CSF cDNAs were examined
in the T cell thyoma cell line, EL4, prior to and after treatment
with the phorbol ester, PMA, for 24 h. While GM-CSF cDNAs
were detected in unstimulated EL4 cells, their levels increased
upon stimulation with PMA. In addition, IL-3 cDNAs were
Figure 10 Detection of autocrine growth factor activity in
∆MEK1:ER and BCL2 infected cells. The ability of the supernatants to
support 3H-thymidine incorporation in the parental cells was
determined (panels a and b). Panel (a) (ρ) supernatant from
FD/∆MEK1:ER+BCL2(Est)c2 cells was titered on the FDC-P1 cell line.
Panel (b) (ρ) supernatant from the TF/∆MEK1:ER+BCL2(Est)c1 cells
was titered on the TF-1 cell line. The ability of the supernatant
prepared from FD/∆MEK1:ER+BCL2(Est)c2 and TF/∆MEK1:ER+BCL2
(Est)c1 cells to support the growth of the respective parental cells
was determined (Panels c and d). Panel (c) FDC-P1 cells cultured
with: (Κ) 10 % WCM), (ρ 10 % supernatant from the
FD/∆MEK1:ER+BCL2(Est)c2 cells), (Γ 1 µm β-estradiol) and (Π no
addition). Panel (d) TF-1 cells cultured with: (Κ 500 pg/ml GM-CSF),
(ρ 10 % supernatant from the TF/∆MEK1:ER+BCL2(Est)c2 cells), (Γ 1
µm β-estradiol) and (Π no addition). Panel (e) Inhibition of
∆MEK1:ER+BCL2-mediated growth by αGM-CSF antibodies. The
effects of monoclonal antibodies to GM-CSF and IL-3 on 3H-
thymidine incorporation was determined (Panel e). Controls were an
α-murine IL-6 Ab for the FD/∆MEK1:ER+BCL2(Est)c2 cells and α-
human IGF1R for the human TF/∆MEK1:ER+BCL2(Est)c1 cells.
detected upon PMA stimulation. cDNAs encoding either IL-3
or GM-CSF were not detected in FDC-P1, FD/BCL2(IL3)Pool,
FD/∆MEK1:ER(IL3)c1, TF-1, TF/BCL2(GM)Pool, TF/∆MEK1:
ER(GM)Pool or TF/∆MEK1:ER+BCL2(GM)Pool cells which
remained cytokine-dependent. cDNAs encoding GM-CSF but
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Figure 11 Presence of autocrine GM-CSF transcripts in ∆MEK1:ER and BCL2 infected cells. The identity of the cytokines secreted by
∆MEK1:ER and BCL2 infected cells was further confirmed by RT-PCR analysis performed on mRNA samples from the cells. The EL-4 thymoma
cell line was used as a control. Higher levels of GM-CSF cDNA transcripts were detected when EL-4 cells were stimulated with PMA than in
unstimulated EL4 cells. Similar amounts of mRNAs were used in the RT-PCR analysis as determined by the relatively equal levels of
β2-microglobulin and β-actin cDNAs detected.
not IL-3 were detected in the MEK1-responsive cells implicat-
ing a possible autocrine mechanism of transformation. Usually
higher levels of GM-CSF cDNAs were detected in the MEK1-
responsive FD/∆MEK1:ER+BCL2(Est)c2 and TF/∆MEK1:ER+
BCL2(Est)c1 cells than in the FD/∆MEK1:ER+LNL6(Est)c4 and
TF/∆MEK1:ER+LNL6(Est)c1 cells. Thus, conversion of hemato-
poietic cells to MEK1-responsive growth in the presence of
constitutive BCL2 expression was associated with the
production of autocrine GM-CSF.
Discussion
We recently reported that infection of two different cytokine-
dependent hematopoietic cell lines, murine FDC-P1 and
human TF-1, with a ∆MEK1:ER containing retrovirus resulted
in the isolation of cells with two growth factor pheno-
types, cytokine-dependent and MEK1-responsive (cytokine-
independent).39,74 However, both types of cells expressed the
∆MEK1:ER oncoprotein. Due to the relatively low frequency
of isolation of MEK1-responsive cells, we sought to examine if
there were other genes which could interact with the activated
MEK1 oncoprotein to relieve the cytokine-dependence of
FDC-P1 and TF-1 cells. Bcl-2 was chosen as a gene to exam-
ine as other investigators have previously shown that members
of the Raf/MEK/MAPK pathway may interact with BCL2 in
order to regulate apoptosis.65,66 Raf has been shown to associ-
ate with BCL2, and it has been suggested that the association
of Raf with BCL2 allows for the phosphorylation of BCL2 by
Raf, as well as the translocation of Raf to the mitochondria
where it may phosphorylate additional targets.65,66 Moreover,
the downstream ERK2 and p90Rsk kinases may phosphorylate
BCL2 at a key serine residue near the amino terminal end.
Phosphorylation of BCL2 at this site is believed to convey
BCL2 with its anti-apoptotic ability.68–70,72,73 Earlier analysis
of the cytokine-dependent and MEK1-responsive FDC-P1 and
TF-1 cells indicated that MEK1 activation in the MEK1-respon-
sive cells resulted in the suppression of apoptosis, whereas
MEK1 activation in the cytokine-dependent cells was unable
to significantly suppress apoptosis (data not published).
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In this study, the cytokine-dependent ∆MEK1:ER cells were
infected with a retrovirus encoding BCL2 or the empty retrovi-
ral vector, LNL6, as a control. Infection with the BCL2 retro-
virus increased the recovery of MEK1-responsive ∆MEK1:ER
cells approximately 10-fold as compared to infection with the
empty retroviral vector. Thus, BCL2 overexpression could
compliment aberrant MEK1 activation and increase the recov-
ery of cytokine-independent cells. Although BCL2 over-
expression was able to prolong survival of these cells, the
growth of these MEK1-responsive cells was conditional as
removal of β-estradiol eliminated growth and eventually
induced apoptosis.
The possibility of endogenous estrogen receptors func-
tioning in synergy with MEK1 and BCL2 was excluded by the
use of the estrogen receptor antagonist 4-OH Tamoxifen. The
MEK1-responsive cells maintained the ability to incorporate
3H-thymidine even when endogenous estrogen receptor
activation was antagonized.
Cytokine-dependent FDC-P1 and FD/BCL2 cells were found
to exit the cell cycle after cytokine withdrawal and only re-
enter the cell cycle when IL-3 was added. In contrast, a small
percentage of cytokine-dependent FD/∆MEK1:ER+LNL6 cells
were found to remain in S phase after IL-3 withdrawal as mea-
sured by both cell cycle FACS analysis and 3H-thymidine
incorporation. These same cytokine-dependent FD/∆MEK1:
ER+LNL6 cells entered the cell cycle when IL-3 was added as
was observed in the cytokine-dependent cells which lacked
the ∆MEK1:ER protein, but these cells also enter S phase in
response to 4-HT. Although some of these cells were able to
enter S phase, these cytokine-dependent FD/∆MEK1:ER+LNL6
cells were unable to enter G2/M and complete the cell cycle.
In contrast, the MEK1-responsive FD/∆MEK1:ER+LNL6 and
FD/∆MEK1:ER+BCL2 cells showed a less drastic cell cycle
progression profile as a significant percentage of the cells
remained in S and G2/M phases after cytokine withdrawal and
addition of no growth factor. This is likely due to the high
level of autocrine growth factor synthesis which promoted
growth for a limited time period in the absence of exogenous
cytokines and 4-OH-Tamoxifen.
The effects of cytokine withdrawal on the inhibition of cell
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growth in the two different types of conditionally transformed
factor-independent cells was varied, as the MEK1-responsive
FD/∆MEK1:ER+LNL6 cells would undergo apoptosis after 1
day of cytokine withdrawal whereas the BCL2-infected MEK1-
responsive cells took longer to undergo apoptosis. In both
cases apoptosis was prevented in the MEK1-responsive cells
when they were treated with either IL-3 or β-estradiol. This
indicated that while activated ∆MEK1:ER oncoproteins were
necessary for estradiol-responsive growth, BCL2 over-
expression could result in an increase in cell viability when
the conditionally transformed cells were deprived of both
cytokine and β-estradiol. This suppression of apoptosis could
be due not only to the presence of BCL2 alone, but also to
the high level of GM-CSF expression. In addition, while both
∆MEK1:ER+LNL6 and ∆MEK1:ER+BCL2 transformed cells
expressed GM-CSF, higher levels were detected in the
∆MEK1:ER cells which overexpressed BCL2.
Activated MEK1 resulted in the activation of the down-
stream MAP kinases (ERK1 and ERK2). In the ∆MEK1:ER
infected cells, activation of ERK2 was observed to increase
approximately 15–30 min after ∆MEK1:ER activation. Interest-
ingly, in MEK1-responsive FD/∆MEK1:ER cells there was a
second peak of ERK2 activity around 8–12 h after addition of
β-estradiol which remained elevated for up to 24 h. This is
likely due to the induction of an autocrine loop as treatment
of the cells with β-estradiol induced the expression of GM-
CSF. The level of GM-CSF secreted from the MEK1-responsive
FD/∆MEK1:ER+LNL6 and FD/∆MEK1:ER+BCL2 cells was
found to be sufficient for the maintenance and proliferation of
the parental FDC-P1 and TF-1 cells. In addition, the autocrine
GM-CSF was required for the proliferation of the MEK1-
responsive cells. These cells suggest a synergistic role for
underlying anti-apoptotic signals in conjunction with prolifer-
ative signal transduction alterations during the development
of myelodysplastic disease and provide an interesting model
to elucidate the effects of MEK1 and BCL2 oncoproteins on
hematopoietic cell growth, cell cycle progression, prevention
of apoptosis and malignant transformation. Identification of
pathways which cross-talk with the Ras/Raf/MEK/MAPK path-
way to promote cellular transformation and prevent apoptosis
will aid in our understanding of the mechanisms responsible
for tumor progression and will provide targets for chemo-
therapy.
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